Clinical Trial VICCNCPED10101


Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine with or without Campath

Principal Investigator(s)

Haydar Frangoul


  • Protocol No. VICCNCPED10101
  • Open Date: 12/28/2006
  • Staging: NA
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: Improve donor chimerism levels in patients with inherited nonmalignant disorders undergoing HCT using a reduced intensity conditioning regimen either through the addition of Campath or a slightly higher dose of TBI.
  • Disease Sites: Pediatrics; Benign Hematologic
  • Therapies: Bone Marrow/Stem Cell Transplant; Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy
  • Drugs: Campath-1H; Fludarabine (Fludara)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00553098
  • Secondary Protocol No: 2007.00



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.